Quick Answer
HAEMONETICS CORP reported Cash and Equivalents of $306.76 million for fiscal year 2025.
HAEMONETICS CORP Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $306.76M | +71.6% |
| 2024 | $178.80M | -37.1% |
| 2023 | $284.47M | +9.6% |
| 2022 | $259.50M | +34.9% |
| 2021 | $192.31M | +40.1% |
| 2020 | $137.31M | -18.9% |
| 2019 | $169.35M | -6.0% |
| 2018 | $180.17M | +29.1% |
| 2017 | $139.56M | +21.2% |
| 2016 | $115.12M | -28.3% |
| 2015 | $160.66M | -16.5% |
| 2014 | $192.47M | +7.5% |
| 2013 | $179.12M | -21.7% |
| 2012 | $228.86M | +16.3% |
| 2011 | $196.71M | +39.0% |
| 2010 | $141.56M | -9.7% |
| 2009 | $156.72M | +17.3% |
| 2008 | $133.55M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $363.37M | +13.3% | +22.6% |
| September 30, 2025 | $296.43M | -1.0% | +1.2% |
| June 30, 2025 | $292.90M | -15.0% | -4.5% |
| March 31, 2025 | $306.76M | +71.6% | -4.4% |
| December 31, 2024 | $320.85M | +65.4% | +7.2% |
| September 30, 2024 | $299.28M | -14.7% | -13.1% |
| June 30, 2024 | $344.43M | +20.5% | +92.6% |
| March 31, 2024 | $178.80M | -37.1% | -7.8% |
- HAEMONETICS CORP showed an increase of +71.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, HAEMONETICS CORP’s cash and equivalents has grown by 129.7% (from $133.55 million to $306.76 million).
- The most recent figure is from HAEMONETICS CORP’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 21, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: